Clinical trial · no report yet · Phase 2
NERO
Niraparib Efficacy in Patient With Unresectable Mesothelioma
- NCT05455424 ↗
- Completed
- University Hospital Southampton NHS Foundation Trust
- 4 commentary sources found
- Focused
We haven't built a report for this trial yet. This page shows the registry record and the public commentary we found that names the trial. A report reads that commentary and sets out what clinicians said about the trial, each point linked to its source. How reports are made.
Commentary we found
Podcasts, YouTube videos and X posts in our index that name this trial. A report screens them, searches for more and cites what clinicians said when it is built. Commentary is thin so far, so the report would be short.
| Channel | Found | |
|---|---|---|
| Podcasts | 3 | |
| YouTube | 1 |
The trial
ClinicalTrials.gov- Official title
- Niraparib Efficacy in Patient With Unresectable Mesothelioma: A Randomised Phase II Trial of Niraparib Versus Active Symptom Control in Patients With Previously Treated Mesothelioma
- Phase
- Phase 2
- Status
- Completed
- Conditions
- Mesothelioma, Malignant
- Interventions
- Niraparib Oral Product; Active Symptom Control
- Arms
- Niraparib + ASC · Experimental
- Active Symptom Control · Active comparator
- Enrollment
- 88
- Primary outcomes
- Progression-free survival
- Sponsor
- University Hospital Southampton NHS Foundation Trust with University of Southampton, British Lung Foundation
- Start
- Jul 11, 2022
- Primary completion
- Jan 31, 2025
- Results posted
- No
- Registry record
- NCT05455424 · updated May 15, 2025
Publications
linked from the registry- Fennell D, Griffiths D, Eminton Z, Morgan-Fox A, Hill K, Ewings S, Stuart C, Johnson L, Mallard K, Nye M, Darlison L, Dulloo S, Cave J, Luo JL, Taylor P, Spicer J, Poile C, Bzura A, Griffiths G. Evaluating niraparib versus active symptom control in patients with previously treated mesothelioma (NERO): a study protocol for a multicentre, randomised, two-arm, open-label phase II trial in UK secondary care centres. BMJ Open. 2023 Nov 22;13(11):e073120. doi: 10.1136/bmjopen-2023-073120. PubMed 37993149